Intellia Therapeutics' Gene Therapies Fall Short Of Breakthroughs (Rating Downgrade)
Intellia's Phase 3 trial for NTLA-2002 shows promise, but limitations warrant caution. See why we believe NTLA stock is hold ...
stockhead19h
Perpetual Resources
Babarczy is a successful and experienced finance industry professional, having worked as a Portfolio Manager for close to 15 years. Julian has extensive experience investing across all areas of the ...